HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00616798

Safety study of RO4917838 in Schizophrenia

Medication studyAges 18–60Multiple countries
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 60 years.

Listed locations
Granada Hills and 72 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study clarity

Study information

Study start dateMarch 2008
Recruitment status
Completed
Enrollment listed in the registry
323
Sponsor
Hoffmann-La Roche
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, France, Austria, ...
Age range
From 18 Years to 60 Years
Official registry ID
NCT00616798
Official title
Show the full official title

Randomized, Double-blind, Placebo-controlled add-on Trial of the Safety and Efficacy of RO4917838 in Outpatients on Select Atypical Antipsychotics With Prominent Negative or Disorganized Thought Symptoms

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Granada Hills, United States · Los Angeles, United States · Oceanside, United States

54 more locations
  • Torrance, United States
  • Atlanta, United States
  • Hoffman Estates, United States
  • Brooklyn, United States
  • Cincinnati, United States
  • Oklahoma City, United States
  • Philadelphia, United States
  • Austin, United States
  • DeSoto, United States
  • Irving, United States
  • Vienna, Austria
  • Curitiba, Brazil
  • Pelotas, Brazil
  • Rio de Janeiro, Brazil
  • Salvador, Brazil
  • São Paulo, Brazil
  • Marseille, France
  • Orvault, France
  • Toulon, France
  • Achim, Germany
  • Bochum, Germany
  • Freiburg im Breisgau, Germany
  • Hamburg, Germany
  • Nuremberg, Germany
  • Westerstede, Germany
  • Balassagyarmat, Hungary
  • Budapest, Hungary
  • GYR, Hungary
  • Gyula, Hungary
  • Nyíregyháza, Hungary
  • Aichi, Japan
  • Chiba, Japan
  • Fukuoka, Japan
  • Gunma, Japan
  • Kanagawa, Japan
  • Nagasaki, Japan
  • Saga, Japan
  • Sapporo, Japan
  • Tokushima, Japan
  • Tokyo, Japan
  • Mexico City, Mexico
  • Monterrey, Mexico
  • Bydgoszcz, Poland
  • Kielce, Poland
  • Skorzewo, Poland
  • Torun, Poland
  • Tuszyn, Poland
  • Żuromin, Poland
  • Kazan', Russia
  • Lipetsk, Russia
  • Moscow, Russia
  • Nizhny Novgorod, Russia
  • Saint Petersburg, Russia
  • Russia
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Hoffmann-La Roche.

Did this study involve medication?

Yes. The study involved medication, including RO4917838 and Placebo.

Who was this study for?

Listed age limits: 18 years to 60 years.

Want to explore more studies?

Explore studies